Muhammed B. Sabdia

Brisbane, QLD, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.

Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.

Journal: American journal of hematology

Published: June 10, 2024

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

Journal: EBioMedicine

Published: March 24, 2024

Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillance.

Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillance.

Journal: Haematologica

Published: November 01, 2023

The IRE1α Endonuclease Plays a Dual Role in Regulating the XBP1/miRNA-34a Axis and PD-1 Expression within Natural Killer Cells in Hodgkin Lymphoma.

The IRE1α Endonuclease Plays a Dual Role in Regulating the XBP1/miRNA-34a Axis and PD-1 Expression within Natural Killer Cells in Hodgkin Lymphoma.

Journal: Acta haematologica

Published: May 17, 2023

Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.

Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.

Journal: Acta haematologica

Published: June 24, 2022

Neoantigens - the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders.

Neoantigens - the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders.

Journal: Blood reviews

Published: February 18, 2022

Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression.

Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression.

Journal: Cancers

Published: July 13, 2021

Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy.

Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy.

Journal: Clinical & translational immunology

Published: May 28, 2021

Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cells.

Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cells.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: January 27, 2021

Genetic aberrations of NLRC5 are associated with downregulated MHC-I antigen presentation and impaired T-cell immunity in follicular lymphoma.

Genetic aberrations of NLRC5 are associated with downregulated MHC-I antigen presentation and impaired T-cell immunity in follicular lymphoma.

Journal: EJHaem

Published: August 25, 2020

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Journal: Blood

Published: August 05, 2020

Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma.

Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma.

Journal: Blood advances

Published: April 03, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026